ArticleBMC ophthalmology2025
Five-year outcomes of trabeculo-canalectomy for Chinese PACG patients: a retrospective study.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Two-year outcomes of trabeculo-canalectomy for glaucoma secondary to iridocorneal endothelial syndrome: a retrospective study.Frontiers in medicine · 2026Article
- Two-year outcomes of modified external suture trabeculotomy for Chinese open-angle glaucoma patients.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo evaluate the 5-year outcomes of trabeculo-canalectomy in the treatment of primary angle-closure glaucoma (PACG) among Chinese patients.
methodsA retrospective study was designed, involving 46 PACG patients (50 eyes) treated with trabeculo-canalectomy at the First Affiliated Hospital of Nanjing Medical University from January 2016 to December 2018. The patients were followed up at 1 week, 1 month, 3 months, 6 months, 12 months, 1 year, 2 years and 5 years. Surgical success was defined as intraocular pressure (IOP) ≤ 21 mmHg (1 mmHg = 0.133 kPa) under glaucoma medication (qualified success) and without any glaucoma medication (absolute success). Main outcomes were measured according to IOP, number of medication regimens, surgical success rate, complications, and filtering bleb status.
resultsA total of 46 PACG patients (50 eyes) were finally included for statistical analysis, with a mean age of 56.68 ± 6.75 years (range, 41-69 years). The mean preoperative IOP was 30.72 ± 10.26 mmHg with a median number of medication regimens of 2 (range, 0 to 4). Compared to those before the operation, the mean IOP decreased to 12.15 ± 3.11, 14.33 ± 4.10, 15.68 ± 4.24, 16.45 ± 4.14, 16.95 ± 3.51, 17.67 ± 3.15 and 17.04 ± 3.78 mmHg at 1 week, 1 month, 3 months, 6 months, 12 months, 1 year, 2 years and 5 years, respectively. The median (range) numbers of medication regimens were 0 (0 ~ 1), 0 (0 ~ 2), 0 (0 ~ 2), 0 (0 ~ 2), 0 (0 ~ 2), 0 (0 ~ 3), 0 (0 ~ 3), 0 (0 ~ 3) at the eight time points, respectively. The mean postoperative IOP and the number of medication regimens at each time point were significantly lower than those before operation (all P < 0.01). The 5-year total success rate was 89%, and the absolute success rate was 78%. Shallow anterior chamber (10%) and hyphema (12%) were the most common complications early after surgery. At 3 months, anterior segment slit-lamp photography and ultrasound biomicroscopy showed no obvious filtering blebs in 50 eyes (100%). IOP increased transiently in 6 eyes (12%) within 1 month after surgery.
conclusionSimple and cost-saving trabeculo-canalectomy provides favorable 5-year outcomes in the treatment of medically uncontrolled PACG, as shown by more effective IOP control, more obvious drug reduction, as well as fewer post-operative interventions compared to trabeculectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.